Physician profile
Laurel E Duffy
NPI 1841982121
$2,869.14
in general payments reported to CMS, 2019-2025
20 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 88% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $338 · 2024: $1,306 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,869.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $468.08 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $431.62 | 2023-2025 | |
| Novo Nordisk INC | $417.73 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.07 | 2023-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $178.94 | 2023-2025 | Onpattro |
| Amgen INC. | $128.53 | 2023-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals International, Plc | $116.21 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $103.74 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $94.46 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $89.62 | 2023-2025 | Verquvo, Belsomra |
| Pfizer INC. | $86.54 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $79.91 | 2023-2024 | Xarelto |
| Eisai INC. | $74.94 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $61.06 | 2024 | Opsumit |
| Esperion Therapeutics, INC. | $58.00 | 2024 | Nexletol |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $52.47 | 2025 | Camzyos |
| Exact Sciences Corporation | $47.34 | 2024-2025 | Cologuard Collection Kit |
| Lexicon Pharmaceuticals, INC. | $46.14 | 2023 | Inpefa |
| Glaxosmithkline, LLC. | $39.37 | 2024-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $14.37 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Duffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.